Drug prolongs lives of lung cancer patients, says study
The cancer drug Erbitux prolonged the lives of patients with advanced lung cancer by five weeks, according to a new clinical study described as an important gain for such individuals. "Patients with advanced NSCLC (non-small cell lung cancer) have limited treatment options and life expectancy is short, so the survival increase shown in this study is an important step for these patients,' said Robert Pirker of the Medical University of Vienna, a lead investigator in the study.